|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 15, 2000
SANGSTAT MEDICAL CORPORATION (Exact name of registrant as specified in its charter)
|
|
|
|
6300 Dumbarton Circle
Fremont, California 94555
(Address of principal executive offices including zip code)
510-789-4300
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Item 5. Other Matters
On May 15, 2000, SangStat announced that the United States Food and Drug Administration has approved Abbott Laboratories' Gengraf™ capsules (cyclosporine capsules, USP [MODIFIED]). SangStat and Abbott will be co-promoting Gengraf™.
The foregoing changes are discussed in greater detail in SangStat's press release, a copy of which is filed herewith as exhibit 99.1.
Item 7. Financial Statements and Exhibits
(a) Financial statements of business acquired. - Not applicable
(b) Pro forma financial information. - Not applicable
(c) Exhibits.
|
Description |
|
Press release dated May 15, 2000. |
SIGNATURES
Pursuant to the requirement of the Security Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 17, 2000
SANGSTAT MEDICAL CORPORATION |
By: | /s/ Stephen G. Dance |
| |
Stephen G. Dance | |
Senior Vice President, Finance |
EXHIBIT INDEX
|
Description |
|
Press release dated May 15, 2000. |
|